In contrast, in early studies, passive transfer of antibodies against heparan sulfate proteoglycans was reported to induce GBM abnormalities and proteinuria; however, these antibodies may target other proteoglycans, such as agrin, in addition to perlecan [15]. The gene discussed is HSPG2; the disease is glioblastoma.